News

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Immunotherapy Web Featured Images 109

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.

Read more
News medical 3

CAR-T cells engineered to target a common genetic alteration: Loss of heterozyg...

  Mar 18 2021 Tagged CAR-T

Researchers developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers.

Visit website
Onclive26

Frontline Axi-Cel Elicits 74% CR Rate in High-Risk Large B-Cell Lymphoma

Axicabtagene ciloleucel elicited a high objective response rate of 85%, with a complete response rate of 74% when used as a first-line therapy in patients with high-risk large B-cell lymphoma.

Visit website
onclive7

Risk-Adapted CAR T Dosing Maintains Efficacy, Improves Safety in Pediatric Relap...

A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden.

Visit website
Onclive28

Brexucabtagene Autoleucel Displays Continued Durability, Safety in Relapsed/Refr...

Brexucabtagene autoleucel displayed significant and durable responses and a reduction in adverse effects in patients with relapsed/refractory mantle cell lymphoma.

Visit website
Onclive27

Teclistamab Shows Continued Promise in R/R MM: Updated phase 1 results

Teclistamab demonstrated encouraging clinical activity, along with a tolerable safety profile, in patients with relapsed/refractory multiple myeloma.

Visit website
targeted15

Therapeutic options for Treatment-Naïve Chronic Leukocytic Leukemia

During a virtual Targeted Oncology Case-Based Roundtable event, Daniel O. Persky, MD, reviewed the case of a 61-year-old patient with chronic lymphocytic leukemia.

Visit website
Immunotherapy Web Featured Images 109

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.

Read more
Immunotherapy Web Featured Images 123

Experimental safety switch reduces severity of CAR-T immunotherapy-related side ...

UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.

Visit website
Immunotherapy Web Featured Images 1

Bispecific Antibodies Could Be the Next Big Advance in Oncology

  Mar 11 2021 Tagged mAbs, BiTE

Human monoclonal antibody therapies are among the fastest growing categories in the cancer pipeline, with more than 570 agents in clinical development. Now, a new type of antibody-based therapy may overcome the limitations of monoclonal antibodies, and it has the potential to disrupt the current treatment paradigm in oncology.

Visit website